Moreover, CAPE exerts its antimetastatic effects in oral cancer by downregulating the expression of matrix metalloproteinase-2 (MMP-2) following the failure of focal adhesion kinase (FAK) and MAPK signaling activation [11]. The gene discussed is MMP2; the disease is lip and oral cavity carcinoma.